Anemia: A Connection Between Heart Failure and Kidney Failure

Link to article at PubMed

Cardiol Clin. 2021 Aug;39(3):319-333. doi: 10.1016/j.ccl.2021.04.003.


Erythropoiesis-stimulating agents (ESAs) have improved the quality of life and reduced the need for transfusions in patients with chronic kidney disease. However, randomized trials showed no benefit but possible safety issues following high doses of ESAs given to reach normal hemoglobin levels. Iron therapy is used together with ESA; when given proactively, it may reduce the risk of mortality and cardiovascular events in hemodialysis patients. Recent trials also showed benefits of intravenous iron therapy in patients with heart failure. New drugs for correcting anemia may retain the present efficacy of ESAs as antianemic drugs and reduce cardiovascular risks.

PMID:34247747 | DOI:10.1016/j.ccl.2021.04.003

Leave a Reply

Your email address will not be published.